Acute Myeloid Leukemia - Adolescents Clinical Trial
CALGB 10403: An Intergroup Phase II Clinical Trial for Adolescents and Young Adults With Untreated Acute Lymphoblastic Leukemia (ALL)
Protocol ID
Protocol Description
The purpose of this study is to improve the outcome of adolescents and young adults with acute lymphoblastic leukemia (ALL). This study will evaluate the effectiveness and side-effects of an intensive program using multiple chemotherapy drugs that has been designed for children but is now being used in young adults up to 30 years old. We will compare the outcomes of patients treated by adult hematologists and oncologists on this study with the outcomes of similar patients treated with the same chemotherapy program by pediatric oncologists (doctors who specialize in the treatment of cancer in children).
One of the important goals of this study is to deliver this treatment with as little delay or variation in treatment doses as possible. We are testing whether or not young adults have better outcomes if all of the prescribed therapy is given on time.
Eligibility Criteria
Adolescents and young adults with acute lymphoblastic leukemia (ALL)
Primary Investigator(s)
- Jonathan Kolitz, MD